MEDRAD MRXperion MR Injection System and MR Injection System Syringe Kit; MEDRAD IS12 Module (IS12); MEDRAD Imaging Bulk Package Transfer Spike
Bayer Medical Care, Inc. · Decision date Oct 6, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-06 for K262043, a traditional 510(k) received 06/17/2026 from Bayer Medical Care, Inc. of Indianola, Pennsylvania. The listed device name covers the MEDRAD® MRXperion MR Injection System and MR Injection System Syringe Kit, the MEDRAD® IS12 Module (IS12), and the MEDRAD® Imaging Bulk Package Transfer Spike. The classification name is Injector And Syringe, Angiographic, under regulation 870.1650, with product code DXT and subsequent product code PQH; the regulation medical specialty is Cardiovascular and the review panel General Hospital.
SESE means FDA found the submission substantially equivalent to a legally marketed predicate device; it is a 510(k) clearance, not premarket approval. The page states the submission was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan. The record does not identify the predicate device, describe the specific changes or components submitted, or include a summary statement, so the technical basis for the equivalence finding remains unknown from this source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 6, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262043
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Bayer Medical Care, Inc.
- Product code
- DXT
- Decision code
- SESE
- Decision date
- Oct 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Injector And Syringe, Angiographic.
- Applicant
- Bayer Medical Care, Inc.
- Product code
- DXT
- FDA device class
- 2
FDA decision timeline
K262043 received
Application receipt date recorded by FDA.
K262043 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bayer Medical Care, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Indianola, PA
Sources and methodology
- Original FDA record: K262043
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records